Vedolizumab Selectivity — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — It blocks alpha4-beta7-mediated lymphocyte trafficking primarily to gut mucosa
The best answer is “It blocks alpha4-beta7-mediated lymphocyte trafficking primarily to gut mucosa”. Vedolizumab targets the alpha4-beta7 integrin interaction with MAdCAM-1, preferentially limiting lymphocyte homing to the gastrointestinal tract. This gut selectivity reduces, but does not eliminate, systemic infection and vaccine considerations. The other mechanisms describe unrelated biologic or small-molecule therapies.
Reference: Gastroenterological Society of Australia: Clinical practice resources for inflammatory bowel disease: https://gesa.org.au/Web/Resources/Clinical_Practice_Resources.aspx